{
  "actions": [
    {
      "acted_at": "2003-01-27",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2003-01-27",
      "action_code": "H11100",
      "committees": [
        "HSWM"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on Ways and Means.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr354-108",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Ways and Means",
      "committee_id": "HSWM"
    }
  ],
  "congress": "108",
  "cosponsors": [],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2003-01-27",
  "number": "354",
  "official_title": "To amend the Internal Revenue Code of 1986 to allow drug manufacturers a credit against income tax if they certify that the price of a drug in the United States market is not greater than its price in the Canadian or Mexican market.",
  "popular_title": null,
  "related_bills": [],
  "short_title": "North American Prescription Price Equity Act of 2003",
  "sponsor": {
    "bioguide_id": "D000533",
    "district": "2",
    "name": "Duncan, John J., Jr.",
    "state": "TN",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2003-01-27",
  "subjects": [
    "Canada",
    "Commerce",
    "Drug industry",
    "Health",
    "Income tax",
    "Latin America",
    "Mexico",
    "Prescription pricing",
    "Tax credits",
    "Tax deductions",
    "Taxation",
    "Wholesale trade"
  ],
  "subjects_top_term": "Taxation",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2003-01-27",
    "date": "2006-11-28T17:35:40Z",
    "text": "North American Prescription Price Equity Act of 2003 - Amends the Internal Revenue Code to allow drug manufacturers a limited tax credit if they certify that the wholesale price of a drug in the United States market is not greater than its wholesale price in the Canadian or Mexican market."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "North American Prescription Price Equity Act of 2003",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend the Internal Revenue Code of 1986 to allow drug manufacturers a credit against income tax if they certify that the price of a drug in the United States market is not greater than its price in the Canadian or Mexican market.",
      "type": "official"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "North American Prescription Price Equity Act of 2003",
      "type": "short"
    }
  ],
  "updated_at": "2023-01-15T21:19:40Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/108/hr/BILLSTATUS-108hr354.xml"
}